0001126234false00011262342022-05-092022-05-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

May 9, 2022 (May 4, 2022)

Date of Report (date of earliest event reported)

LUMOS PHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-35342						42-1491350
(State or other jurisdiction of incorporation or organization)			(Commission File Number)						(I.R.S. Employer Identification No.)

4200 Marathon Blvd., Suite 200

Austin, Texas 78756

(Address of Principal Executive Offices)

(512) 215-2630

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock			LUMO			The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 5.07    Submission of Matters to a Vote of Security Holders.

The 2022 Annual Meeting of Stockholders of Lumos Pharma, Inc. (the “Company”) was held May 4, 2022, for the following purposes:

•To elect the nominees for director, An van Es-Johansson, Kevin Lalande and Joseph S. McCracken, nominated by the Board of Directors of the Company (the “Board”), to serve until the 2025 Annual Meeting of Stockholders;

•To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on March 23, 2022 (the “Proxy Statement”);

•To approve the amended Lumos Pharma, Inc. 2010 Employee Stock Purchase Plan, as disclosed in the Proxy Statement; and

•To ratify the selection by the Audit Committee of the Board of KPMG, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.

At the meeting, the stockholders of the Company:

•elected An van Es-Johansson, Kevin Lalande and Joseph S. McCracken as directors of the Company;

•approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as set forth in the Proxy Statement;

•approved the amended Lumos Pharma, Inc. 2010 Employee Stock Purchase Plan, as described in the Proxy Statement; and

•ratified the appointment of KPMG, LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2022.

The final voting results on each of the matters submitted to a vote of stockholders at the 2022 Annual Meeting are as follows:

			Election of Directors			For			Withheld			Broker Non-Votes
1.			An van Es-Johansson			3,974,725			124,674			2,457,834
			Kevin Lalande			4,062,816			36,583			2,457,834
			Joseph S. McCracken			4,072,614			26,785			2,457,834

									For			Against			Abstentions			Broker Non-Votes
2.			Approval, on an advisory basis, of the compensation of the Company’s named executive officers						4,061,654			33,990			3,755			2,457,834

									For			Against			Abstentions			Broker Non-Votes
3.			Approval of the Company’s amended 2010 Employee Stock Purchase Plan						4,054,388			43,596			1,415			2,457,834

									For			Against			Abstentions
4.			Ratification of KPMG, LLP as independent registered public accounting firm for the Company’s fiscal year ending December 31, 2022						6,451,958			104,619			656

---

SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:    May 9, 2022

			LUMOS PHARMA, INC., a Delaware corporation
By:			/s/ Richard J. Hawkins
			Richard J. Hawkins
Its:			Chief Executive Officer